Tämä sivu käännettiin automaattisesti, eikä käännösten tarkkuutta voida taata. Katso englanninkielinen versio lähdetekstiä varten.

A Clinical Study of Raludotatug Deruxtecan in People With Ovarian Cancer (MK-5909-003).

torstai 12. marraskuuta 2026 päivittänyt: Merck Sharp & Dohme LLC

Vaiheen 1B/2 avoin, monikeskustutkimus Raludotutug deruxtecanin turvallisuuden ja tehokkuuden arvioimiseksi muiden syövänvastaisten tutkijoiden kanssa tai ilman sitä, jolla on korkealaatuista seroosista epiteelin munasarjoja, primaarista peritoneaalista tai pullean välineen syöpään, jotka ovat uusiutuneet aikaisemman Platinum-pohjaisen kemoterapian jälkeen

Researchers are looking for other ways to treat high-grade serous and certain other ovarian cancer. High-grade means the cancer cells grow and spread quickly. Serous means the cancer started in the cells that cover the ovaries, the lining of the belly, or in the fallopian tubes.

Standard treatment (usual treatment) for people with high-grade serous ovarian cancer may include:

  • Chemotherapy, which is a treatment that uses medicine to destroy cancer cells or stop them from growing
  • Targeted therapy, which is a treatment that works to control how specific types of cancer cells grow and spread

Raludotatug deruxtecan (R-DXd) is a study treatment that is an antibody drug conjugate (ADC). An ADC attaches to a protein on cancer cells and delivers treatment to destroy those cells. Researchers want to know if R-DXd is safe to take with other treatments and if people tolerate them together. They also want to learn how many people have the cancer respond (gets smaller or goes away) to the treatments.

Tutkimuksen yleiskatsaus

Yksityiskohtainen kuvaus

This study has 2 parts: Part 1 is a dose escalation phase of R-DXd. Part 2 is the expansion phase and will use the Recommended Phase 2 Dose (RP2D) of R-DXd determined in Part 1.

Opintotyyppi

Interventio

Ilmoittautuminen (Arvioitu)

605

Vaihe

  • Vaihe 2
  • Vaihe 1

Yhteystiedot ja paikat

Tässä osiossa on tutkimuksen suorittajien yhteystiedot ja tiedot siitä, missä tämä tutkimus suoritetaan.

Opiskeluyhteys

Opiskelupaikat

    • Victoria
      • St Albans, Victoria, Australia, 3021
        • Rekrytointi
        • Western Health-Sunshine & Footscray Hospitals ( Site 1002)
        • Ottaa yhteyttä:
          • Study Coordinator
          • Puhelinnumero: +61402775432
      • Barcelona, Espanja, 08035
        • Rekrytointi
        • Hospital Universitari Vall d'Hebron-Departamento de Oncologia- VHIO ( Site 0300)
        • Ottaa yhteyttä:
          • Study Coordinator
          • Puhelinnumero: +349325434528607
      • Madrid, Espanja, 28041
        • Rekrytointi
        • Hospital Universitario 12 de Octubre ( Site 0304)
        • Ottaa yhteyttä:
          • Study Coordinator
          • Puhelinnumero: +34913908626
      • Madrid, Espanja, 28040
        • Rekrytointi
        • Hospital Universitario Fundación Jiménez Díaz-START Madrid-FJD ( Site 0303)
        • Ottaa yhteyttä:
          • Study Coordinator
          • Puhelinnumero: 34915504800 x2805
      • Málaga, Espanja, 29010
        • Rekrytointi
        • Hospital Universitario Virgen de la Victoria ( Site 0306)
        • Ottaa yhteyttä:
          • Study Coordinator
          • Puhelinnumero: +34951032508
    • Barcelona
      • L'Hospitalet de Llobregat, Barcelona, Espanja, 08908
        • Rekrytointi
        • Institut Català d'Oncologia - L'Hospitalet ( Site 0302)
        • Ottaa yhteyttä:
          • Study Coordinator
          • Puhelinnumero: +34932607744
    • Madrid
      • Majadhonda, Madrid, Espanja, 28222
        • Rekrytointi
        • HOSPITAL UNIVERSITARIO PUERTA DE HIERRO MAJADAHONDA ( Site 0307)
        • Ottaa yhteyttä:
          • Study Coordinator
          • Puhelinnumero: +34 911917358
    • Madrid, Comunidad de
      • Madrid, Madrid, Comunidad de, Espanja, 28027
        • Rekrytointi
        • Clinica Universidad de Navarra ( Site 0301)
        • Ottaa yhteyttä:
          • Study Coordinator
          • Puhelinnumero: +349135319207513
    • Valenciana, Comunitat
      • Valencia, Valenciana, Comunitat, Espanja, 46014
        • Rekrytointi
        • Hospital General Universitario de Valencia ( Site 0305)
        • Ottaa yhteyttä:
          • Study Coordinator
          • Puhelinnumero: +34 963187527
      • Seoul, Etelä -Korea, 03080
        • Rekrytointi
        • Seoul National University Hospital ( Site 2000)
        • Ottaa yhteyttä:
          • Study Coordinator
          • Puhelinnumero: +82220723511
      • Seoul, Etelä -Korea, 03722
        • Rekrytointi
        • Severance Hospital, Yonsei University Health System ( Site 2002)
        • Ottaa yhteyttä:
          • Study Coordinator
          • Puhelinnumero: +82222282230
      • Seoul, Etelä -Korea, 05505
        • Rekrytointi
        • Asan Medical Center ( Site 2003)
        • Ottaa yhteyttä:
          • Study Coordinator
          • Puhelinnumero: +82230103646
      • Seoul, Etelä -Korea, 06351
        • Rekrytointi
        • Samsung Medical Center ( Site 2001)
        • Ottaa yhteyttä:
          • Study Coordinator
          • Puhelinnumero: 82234101382
    • Kyonggi-do
      • Goyang-si, Kyonggi-do, Etelä -Korea, 10408
        • Rekrytointi
        • National Cancer Center ( Site 2004)
        • Ottaa yhteyttä:
          • Study Coordinator
          • Puhelinnumero: 82319201760
      • Haifa, Israel, 3109601
        • Rekrytointi
        • Rambam Health Care Campus ( Site 0202)
        • Ottaa yhteyttä:
          • Study Coordinator
          • Puhelinnumero: 972-4-7776234
      • Jerusalem, Israel, 9103102
        • Rekrytointi
        • Shaare Zedek Medical Center ( Site 0201)
        • Ottaa yhteyttä:
          • Study Coordinator
          • Puhelinnumero: +972-(0)2-6555424
      • Petah Tikva, Israel, 4941492
        • Rekrytointi
        • Rabin Medical Center ( Site 0203)
        • Ottaa yhteyttä:
          • Study Coordinator
          • Puhelinnumero: +97239378076
      • Ramat Gan, Israel, 5265601
        • Rekrytointi
        • Sheba Medical Center ( Site 0200)
        • Ottaa yhteyttä:
          • Study Coordinator
          • Puhelinnumero: 972-3-5304498
    • Ontario
      • Toronto, Ontario, Kanada, M5G 2M9
        • Rekrytointi
        • Princess Margaret Cancer Centre ( Site 0101)
        • Ottaa yhteyttä:
          • Study Coordinator
          • Puhelinnumero: 416-946-2818
    • Quebec
      • Montreal, Quebec, Kanada, H4A 3J1
        • Rekrytointi
        • McGill University Health Centre ( Site 0100)
        • Ottaa yhteyttä:
          • Study Coordinator
          • Puhelinnumero: 514-934-1934x31975
      • Montreal, Quebec, Kanada, H2X 0A9
        • Rekrytointi
        • Centre Hospitalier de l'Université de Montréal ( Site 0102)
        • Ottaa yhteyttä:
          • Study Coordinator
          • Puhelinnumero: 514-890-8000
      • Sankt Gallen, Sveitsi, 9000
        • Rekrytointi
        • HOCH Health Ostschweiz ( Site 0801)
        • Ottaa yhteyttä:
          • Study Coordinator
          • Puhelinnumero: +41714941111
    • Canton of Basel-City
      • Basel, Canton of Basel-City, Sveitsi, 4031
        • Rekrytointi
        • University Hospital Basel-Gynecology & Gynecologic Oncology ( Site 0802)
        • Ottaa yhteyttä:
          • Study Coordinator
          • Puhelinnumero: +41613284214
    • Canton of Vaud
      • Lausanne, Canton of Vaud, Sveitsi, 1011
        • Rekrytointi
        • CHUV (centre hospitalier universitaire vaudois) ( Site 0800)
        • Ottaa yhteyttä:
          • Study Coordinator
          • Puhelinnumero: +41795567362
      • Taipei, Taiwan, 100225
        • Rekrytointi
        • National Taiwan University Hospital ( Site 3001)
        • Ottaa yhteyttä:
          • Study Coordinator
          • Puhelinnumero: +886223123456
      • Taoyuan, Taiwan, 33305
        • Rekrytointi
        • Chang Gung Medical Foundation-Linkou Branch ( Site 3002)
        • Ottaa yhteyttä:
          • Study Coordinator
          • Puhelinnumero: +88633281200
      • Manchester, Yhdistynyt kuningaskunta, M20 4BX
        • Rekrytointi
        • The Christie NHS Foundation Trust ( Site 0405)
        • Ottaa yhteyttä:
          • Study Coordinator
          • Puhelinnumero: +441619187689
    • East Sussex
      • Brighton, East Sussex, Yhdistynyt kuningaskunta, BN2 1ES
        • Rekrytointi
        • University Hospitals Sussex NHS Foundation Trust ( Site 0404)
        • Ottaa yhteyttä:
          • Study Coordinator
          • Puhelinnumero: +44 01273 696 955
    • England
      • Fulham, England, Yhdistynyt kuningaskunta, SW3 6JJ
        • Rekrytointi
        • Royal Marsden Hospital ( Site 0402)
        • Ottaa yhteyttä:
          • Study Coordinator
          • Puhelinnumero: +442078118084
      • Sutton, England, Yhdistynyt kuningaskunta, SM2 5PT
        • Rekrytointi
        • The Royal Marsden NHS Foundation Trust. ( Site 0403)
        • Ottaa yhteyttä:
          • Study Coordinator
          • Puhelinnumero: +442078118084
    • London, City of
      • London, London, City of, Yhdistynyt kuningaskunta, E1 1RD
        • Rekrytointi
        • Barts Health NHS Trust ( Site 0401)
        • Ottaa yhteyttä:
          • Study Coordinator
          • Puhelinnumero: 020 7377 7000
      • London, London, City of, Yhdistynyt kuningaskunta, SE1 3SS
        • Rekrytointi
        • Guy s & St Thomas NHS Foundation Trust ( Site 0400)
        • Ottaa yhteyttä:
          • Study Coordinator
          • Puhelinnumero: +44 020 7188 7188
    • Connecticut
      • New Haven, Connecticut, Yhdysvallat, 06510
        • Rekrytointi
        • Yale-New Haven Hospital-Smilow Cancer Hospital at Yale-New Haven ( Site 0019)
        • Ottaa yhteyttä:
          • Study Coordinator
          • Puhelinnumero: 203-785-2404
    • Kentucky
      • Louisville, Kentucky, Yhdysvallat, 40202
        • Rekrytointi
        • The University of Louisville, James Graham Brown Cancer Center ( Site 0009)
        • Ottaa yhteyttä:
          • Study Coordinator
          • Puhelinnumero: 502-562-3429
    • Louisiana
      • Shreveport, Louisiana, Yhdysvallat, 71103
        • Rekrytointi
        • TRIALS 365 ( Site 0020)
        • Ottaa yhteyttä:
          • Study Coordinator
          • Puhelinnumero: 318-408-1198
    • Massachusetts
      • Boston, Massachusetts, Yhdysvallat, 02215
        • Rekrytointi
        • Dana-Farber Cancer Institute ( Site 0015)
        • Ottaa yhteyttä:
          • Study Coordinator
          • Puhelinnumero: 877-338-7425
    • New York
      • New York, New York, Yhdysvallat, 10065
        • Rekrytointi
        • Memorial Sloan Kettering Cancer Center ( Site 0003)
        • Ottaa yhteyttä:
          • Study Coordinator
          • Puhelinnumero: 212-639-2000
    • Oklahoma
      • Oklahoma City, Oklahoma, Yhdysvallat, 73104
        • Rekrytointi
        • OU Health University of Oklahoma Medical Center ( Site 7000)
        • Ottaa yhteyttä:
          • Study Coordinator
          • Puhelinnumero: 405-271-1112
    • Texas
      • Fort Worth, Texas, Yhdysvallat, 76104
        • Rekrytointi
        • Texas Oncology - DFW ( Site 8000)
        • Ottaa yhteyttä:
          • Study Coordinator
          • Puhelinnumero: 615-329-7430
      • Houston, Texas, Yhdysvallat, 77030
        • Valmis
        • Houston Methodist Hospital ( Site 0010)
    • Utah
      • West Valley City, Utah, Yhdysvallat, 84119
        • Rekrytointi
        • START Mountain Region ( Site 0008)
        • Ottaa yhteyttä:
          • Study Coordinator
          • Puhelinnumero: 801-907-4750
    • Virginia
      • Charlottesville, Virginia, Yhdysvallat, 22908
        • Rekrytointi
        • University of Virginia Health System ( Site 0011)
        • Ottaa yhteyttä:
          • Study Coordinator
          • Puhelinnumero: 434-924-9333

Osallistumiskriteerit

Tutkijat etsivät ihmisiä, jotka sopivat tiettyyn kuvaukseen, jota kutsutaan kelpoisuuskriteereiksi. Joitakin esimerkkejä näistä kriteereistä ovat henkilön yleinen terveydentila tai aiemmat hoidot.

Kelpoisuusvaatimukset

Opintokelpoiset iät

18 vuotta ja vanhemmat (Aikuinen, Vanhempi Aikuinen)

Hyväksyy terveitä vapaaehtoisia

Ei

Sukupuolet, jotka voivat opiskella

Nainen

Kuvaus

Inclusion Criteria:

  • Has pathologically documented diagnosis of high-grade serous or high-grade endometrioid epithelial ovarian cancer, primary peritoneal cancer, or fallopian tube cancer
  • Participants in Part 1 cohorts and Part 2 Cohort A-2 Arms 1, 2, and 3, Cohort B-2, and Cohort C-2 Arm 3: Has measurable disease per Response Evaluation Criteria In Solid Tumors 1.1
  • Participants in Cohort A-1 Arms 2 and 3: Has relapsed disease after 1 to 3 prior lines of therapy and radiographic evidence of disease progression ≥6 months (≥180 days) after the last dose of platinum-based therapy (ie, platinum-sensitive disease)
  • Participants in Cohort B-1 and Cohort B-2: Has relapsed disease after 1 to 3 prior lines of therapy and radiographic evidence of disease progression <6 months (<180 days) after the last dose of platinum-based therapy (ie, platinum-resistant disease). Participants must have received no more than 1 prior bevacizumab-containing systemic treatment regimen
  • Participants in Cohort B-1, Cohort B-2, Cohort C-2 Arm 3, Cohort E-1 and if administering bevacizumab is planned in Cohort D or Cohort A-2 Arms 1, 2, or 3: Is a candidate for bevacizumab treatment
  • Has provided tumor tissue for biomarker research (all cohorts)
  • Has an Eastern Cooperative Oncology Group performance status of 0 to 1
  • Participants in Cohort C-1, Cohort C-2 Arm 3, Cohort D, and Cohort E-1: Has relapsed disease after 1 prior line of therapy, radiographic evidence of disease progression ≥6 months (≥180 days) after the last dose of platinum-based therapy (ie, platinum-sensitive disease) and progressed during prior treatment with poly-ADP ribose polymerase inhibitor (PARPi) in the first-line setting
  • Participants in Cohort A-2 Arms 1, 2, and 3: Has relapsed disease after 1 prior line of therapy and radiographic evidence of disease progression ≥6 months (≥180 days) after the last dose of platinum-based therapy (ie, platinum-sensitive disease)
  • Participants in Cohort C-2 Arms 1 and 2: Has a new, histologically confirmed diagnosis of International Federation of Gynecology and Obstetrics Stage III or Stage IV epithelial ovarian cancer (high-grade serous or high-grade endometrioid), fallopian tube cancer, or primary peritoneal cancer that is non-homologous recombination deficiency-positive
  • Participants in Cohort C-2 Arms 1 and 2: According to the investigator's assessment, PARPi first-line maintenance treatment for non- homologous recombination deficiency (HRD)-positive disease is not the preferred option for the participant
  • Participants in Cohort C-2 Arms 1 and 2: According to the investigator's assessment, bevacizumab treatment for non-HRD-positive disease is not the preferred option for the participant

Exclusion Criteria:

  • Has any of the following within 6 months before allocation/randomization: cerebrovascular accident, transient ischemic attack, or other arterial thromboembolic event
  • Has uncontrolled or significant cardiovascular disease
  • Has clinically severe pulmonary compromise resulting from intercurrent pulmonary illnesses including, but not limited to, any underlying pulmonary disorder, and any autoimmune, connective tissue, or inflammatory disorders with potential pulmonary involvement, or prior pneumonectomy
  • Has ≥Grade 2 peripheral neuropathy
  • Has received prior treatment with cadherin-6-targeted agents
  • Has received prior systemic anticancer therapy including investigational agents within 4 weeks or 5 half-lives (whichever is shorter) before allocation
  • Has received prior radiotherapy within 2 weeks of the start of study intervention, or has radiation-related toxicities, requiring corticosteroids
  • Receives chronic steroid treatment
  • Has known additional malignancy that is progressing or has required active treatment within the past 3 years
  • Has known active CNS metastases and/or carcinomatous meningitis
  • Has any history of interstitial lung disease (ILD)/pneumonitis irrespective of prior steroid use, current ILD, or suspected ILD, or ILD that cannot be ruled out by imaging at screening
  • Has active infection requiring systemic therapy
  • HIV-infected participants with a history of Kaposi's sarcoma and/or Multicentric Castleman's Disease

Opintosuunnitelma

Tässä osiossa on tietoja tutkimussuunnitelmasta, mukaan lukien kuinka tutkimus on suunniteltu ja mitä tutkimuksella mitataan.

Miten tutkimus on suunniteltu?

Suunnittelun yksityiskohdat

  • Ensisijainen käyttötarkoitus: Hoito
  • Jako: Ei satunnaistettu
  • Inventiomalli: Rinnakkaistehtävä
  • Naamiointi: Ei mitään (avoin tarra)

Aseet ja interventiot

Osallistujaryhmä / Arm
Interventio / Hoito
Kokeellinen: Cohort A-1 Arm 1 (R-DXd + Carboplatin Dose 1)

Participants receive escalating doses of intravenous (IV) raludotatug deruxtecan (R-DXd) in combination with carboplatin at Dose 1. Participants can receive up to a maximum of six 3-week cycles of carboplatin (approximately 4 months) and will receive raludotatug deruxtecan until disease progression or discontinuation.

IV infusion on Day 1 of every 3-week cycle.

Muut nimet:
  • MK-5909, R-DXD

IV infusion on Day 1 of every 3-week cycle for a maximum of 6 cycles.

Includes 5-HT3 Serotonin Receptor Antagonist, NK-1 receptor antagonist, and corticosteroid, administered per protocol.

Kokeellinen: Cohort A-1 Arm 2 (R-DXd + Paclitaxel)

Participants receive escalating doses of IV R-DXd in combination with paclitaxel. Participants can receive up to a maximum of six 3-week cycles of paclitaxel (approximately 4 months) and will receive R-DXd until disease progression or discontinuation.

IV infusion on Day 1 of every 3-week cycle.

Muut nimet:
  • MK-5909, R-DXD

Includes 5-HT3 Serotonin Receptor Antagonist, NK-1 receptor antagonist, and corticosteroid, administered per protocol.

IV infusion on Day 1 of every 3-week cycle for a maximum of 6 cycles.

Kokeellinen: Cohort A-1 Arm 3 (R-DXd + Carboplatin Dose 2)

Participants receive escalating doses of intravenous (IV) R-DXd in combination with carboplatin at Dose 2. Participants can receive up to a maximum of six 3-week cycles of carboplatin (approximately 4 months) and will receive R-DXd until disease progression or discontinuation.

IV infusion on Day 1 of every 3-week cycle.

Muut nimet:
  • MK-5909, R-DXD

IV infusion on Day 1 of every 3-week cycle for a maximum of 6 cycles.

Includes 5-HT3 Serotonin Receptor Antagonist, NK-1 receptor antagonist, and corticosteroid, administered per protocol.

Kokeellinen: Cohort B-1 (R-DXd + Bevacizumab)

Participants receive escalating doses of IV R-DXd in combination with bevacizumab until disease progression or discontinuation.

IV infusion on Day 1 of every 3-week cycle.

Muut nimet:
  • MK-5909, R-DXD

Includes 5-HT3 Serotonin Receptor Antagonist, NK-1 receptor antagonist, and corticosteroid, administered per protocol.

IV infusion on Day 1 of every 3-week cycle.

Muut nimet:
  • Sisältää hankinnan perusteella:
  • - Avastin®
  • - Alymsys®
  • - MVASI®
  • - Oyavas®
  • - Zirabev®
  • - Vegzelma®
  • - Aybintio®
  • - Breztri®
Kokeellinen: Cohort B-2 (R-DXd RP2D + Bevacizumab)

Participants with platinum-resistant recurrent ovarian cancer (PRROC) receive recommended Phase 2 dose (RP2D) of IV R-DXd in combination with bevacizumab until disease progression or discontinuation.

IV infusion on Day 1 of every 3-week cycle.

Muut nimet:
  • MK-5909, R-DXD

Includes 5-HT3 Serotonin Receptor Antagonist, NK-1 receptor antagonist, and corticosteroid, administered per protocol.

IV infusion on Day 1 of every 3-week cycle.

Muut nimet:
  • Sisältää hankinnan perusteella:
  • - Avastin®
  • - Alymsys®
  • - MVASI®
  • - Oyavas®
  • - Zirabev®
  • - Vegzelma®
  • - Aybintio®
  • - Breztri®
Kokeellinen: Cohort C-1 (R-DXd + Pembrolizumab)

Participants receive escalating doses of IV R-DXd in combination with pembrolizumab. Participants can receive up to a maximum of thirty-five 3-week cycles of pembrolizumab (approximately 2 years) and will receive R-DXd until disease progression or discontinuation.

IV infusion on Day 1 of every 3-week cycle.

Muut nimet:
  • MK-5909, R-DXD

Includes 5-HT3 Serotonin Receptor Antagonist, NK-1 receptor antagonist, and corticosteroid, administered per protocol.

IV infusion on Day 1 of every 3-week cycle for a maximum of 35 cycles.

Kokeellinen: Cohort D (R-DXd +/- Bevacizumab)

Participants with platinum-sensitive recurrent ovarian cancer (PSROC) receive IV R-DXd in combination with or without bevacizumab until disease progression or discontinuation.

IV infusion on Day 1 of every 3-week cycle.

Muut nimet:
  • MK-5909, R-DXD

Includes 5-HT3 Serotonin Receptor Antagonist, NK-1 receptor antagonist, and corticosteroid, administered per protocol.

IV infusion on Day 1 of every 3-week cycle.

Muut nimet:
  • Sisältää hankinnan perusteella:
  • - Avastin®
  • - Alymsys®
  • - MVASI®
  • - Oyavas®
  • - Zirabev®
  • - Vegzelma®
  • - Aybintio®
  • - Breztri®
Kokeellinen: Cohort A-2 Arm 1 (R-DXd RP2D + Carboplatin +/- Bevacizumab)

Participants with PSROC will receive the RP2D of R-DXd in combination with a maximum of 6 cycles of carboplatin with or without bevacizumab, until disease progression or discontinuation.

IV infusion on Day 1 of every 3-week cycle.

Muut nimet:
  • MK-5909, R-DXD

IV infusion on Day 1 of every 3-week cycle for a maximum of 6 cycles.

Includes 5-HT3 Serotonin Receptor Antagonist, NK-1 receptor antagonist, and corticosteroid, administered per protocol.

IV infusion on Day 1 of every 3-week cycle.

Muut nimet:
  • Sisältää hankinnan perusteella:
  • - Avastin®
  • - Alymsys®
  • - MVASI®
  • - Oyavas®
  • - Zirabev®
  • - Vegzelma®
  • - Aybintio®
  • - Breztri®
Kokeellinen: Cohort A-2 Arm 2 (R-DXd RP2D + Paclitaxel +/- Bevacizumab)

Participants with PSROC will receive the RP2D of R-DXd in combination with a maximum of 6 cycles of paclitaxel with or without bevacizumab, until disease progression or discontinuation.

IV infusion on Day 1 of every 3-week cycle.

Muut nimet:
  • MK-5909, R-DXD

Includes 5-HT3 Serotonin Receptor Antagonist, NK-1 receptor antagonist, and corticosteroid, administered per protocol.

IV infusion on Day 1 of every 3-week cycle for a maximum of 6 cycles.

IV infusion on Day 1 of every 3-week cycle.

Muut nimet:
  • Sisältää hankinnan perusteella:
  • - Avastin®
  • - Alymsys®
  • - MVASI®
  • - Oyavas®
  • - Zirabev®
  • - Vegzelma®
  • - Aybintio®
  • - Breztri®
Active Comparator: Cohort A-2 Arm 3 (Platinum-Based Doublet Chemotherapy +/- Bevacizumab)

Participants with PSROC will receive one of 3 regimens of investigator's choice of platinum-based doublet chemotherapy with or without bevacizumab. Platinum-based doublet chemotherapy will be administered for maximum of 8 cycles. Bevacizumab can be administered until disease progression or discontinuation.

IV infusion on Day 1 of every 3-week cycle for a maximum of 6 cycles.

IV infusion on Day 1 of every 3-week cycle for a maximum of 6 cycles.

IV infusion on Day 1 of every 3-week cycle.

Muut nimet:
  • Sisältää hankinnan perusteella:
  • - Avastin®
  • - Alymsys®
  • - MVASI®
  • - Oyavas®
  • - Zirabev®
  • - Vegzelma®
  • - Aybintio®
  • - Breztri®

IV injection on days 1 and 8 of each 3-week Cycle

IV injection administered on Day 1 of each 4-week cycle

Muut nimet:
  • PLD
Kokeellinen: Cohort E-1 (R-DXd + MK-2010)

Participants receive escalating doses of IV R-DXd in combination with MK-2010. Participants can receive up to a maximum of thirty-five 3-week cycles of MK-2010 (approximately 2 years) and will receive R-DXd until disease progression or discontinuation.

IV infusion on Day 1 of every 3-week cycle.

Muut nimet:
  • MK-5909, R-DXD

Includes 5-HT3 Serotonin Receptor Antagonist, NK-1 receptor antagonist, and corticosteroid, administered per protocol.

IV infusion on Day 1 of every 3-week cycle

Kokeellinen: Cohort C-2 Arm 1 (Carboplatin + Paclitaxel + Pembrolizumab → R-DXd + Pembrolizumab)

Participants will receive carboplatin (Dose 1 or Dose 2), paclitaxel (five 3-week cycles), and pembrolizumab during the induction phase. During the maintenance phase, participants will receive RP2D of IV R-DXd (up to 2 years; participants with PR or SD at 2 years may continue until disease progression) in combination with pembrolizumab (up to thirty-five 3-week cycles).

IV infusion on Day 1 of every 3-week cycle.

Muut nimet:
  • MK-5909, R-DXD

IV infusion on Day 1 of every 3-week cycle for a maximum of 6 cycles.

IV infusion on Day 1 of every 3-week cycle for a maximum of 6 cycles.

IV infusion on Day 1 of every 3-week cycle for a maximum of 35 cycles.

Kokeellinen: Cohort C-2 Arm 2 (Carboplatin + Paclitaxel)

Participants will receive carboplatin (Dose 1 or Dose 2) and paclitaxel (seven 3-week cycles), followed by standard of care observation.

IV infusion on Day 1 of every 3-week cycle for a maximum of 6 cycles.

IV infusion on Day 1 of every 3-week cycle for a maximum of 6 cycles.

Kokeellinen: Cohort C-2 Arm 3 (R-DXd + Pembrolizumab + Bevacizumab)

Participants with PSROC will receive RP2D of R-DXd in combination with pembrolizumab (up to thirty-five 3-week cycles) and bevacizumab until progressive disease.

IV infusion on Day 1 of every 3-week cycle.

Muut nimet:
  • MK-5909, R-DXD

IV infusion on Day 1 of every 3-week cycle.

Muut nimet:
  • Sisältää hankinnan perusteella:
  • - Avastin®
  • - Alymsys®
  • - MVASI®
  • - Oyavas®
  • - Zirabev®
  • - Vegzelma®
  • - Aybintio®
  • - Breztri®

IV infusion on Day 1 of every 3-week cycle for a maximum of 35 cycles.

Mitä tutkimuksessa mitataan?

Ensisijaiset tulostoimenpiteet

Tulosmittaus
Toimenpiteen kuvaus
Aikaikkuna
Part 1: Number of Participants Who Experience a Dose-limiting Toxicity (DLT) Per Common Terminology Criteria for Adverse Events, Version 5.0 (CTCAE v5.0)
Aikaikkuna: Up to 21 days

DLTs are defined as toxicities during the DLT evaluation period that are assessed by the investigator to be possibly, probably, or definitely related to study treatment and include: Grade 4 thrombocytopenia of any duration or Grade 3 thrombocytopenia lasting ≥7 days; Grade 3 or higher thrombocytopenia associated with clinically significant bleeding; Grade 4 lymphocytopenia lasting ≥14 days; Grade 4 anemia of any duration; any other Grade 4 hematologic toxicity lasting ≥7 days; febrile neutropenia Grade 3 or Grade 4 meeting pre-specifications; pre-specified hepatic organ toxicities; all Grade 3 or higher other nonhematologic toxicities except those pre-specified; other pre-specified nonhematologic toxicities; any delay in treatment with the planned dose of ≥21 days or discontinuation of treatment due to a toxicity during the DLT evaluation period, or Grade 5 toxicity. The number of participants with DLTs will be reported.

Up to 21 days
Part 1: Number of Participants with One or More Adverse Events (AEs)
Aikaikkuna: Up to approximately 3 years

An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The number of participants with one or more AEs will be reported.

Up to approximately 3 years
Part 1: Number of Participants who Discontinue Study Intervention Due to an AE
Aikaikkuna: Up to approximately 3 years

An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The number of participants who discontinue study intervention due to an AE will be reported.

Up to approximately 3 years
Part 2: Objective Response Rate (ORR)
Aikaikkuna: Up to approximately 3 years

ORR is defined as the percentage of participants with Complete Response (CR: disappearance of all target lesions) or Partial Response (PR: at least a 30% decrease in the sum of diameters of target lesions) per Response Evaluation Criteria In Solid Tumors Version 1.1 (RECIST 1.1). The percentage of participants who experience CR or PR as assessed by Blinded Independent Central Review (BICR) will be presented.

Up to approximately 3 years
Part 2: Progression Free Survival (PFS) - Cohort C-2 Arm 1 and Arm 2
Aikaikkuna: Up to approximately 3 years

PFS is defined as the time from randomization to the first documented progressive disease (PD) or death due to any cause, whichever occurs first as assessed by Response Criteria in Solid Tumors Version 1.1 (RECIST 1.1). PD is defined as ≥20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of ≥5 mm. The appearance of one or more new lesions is also considered PD. PFS as assessed by blinded independent central review (BICR) will be presented.

Up to approximately 3 years

Toissijaiset tulostoimenpiteet

Tulosmittaus
Toimenpiteen kuvaus
Aikaikkuna
Part 1: Objective Response Rate (ORR)
Aikaikkuna: Up to approximately 3 years

ORR is defined as the percentage of participants who have a confirmed Complete Response (CR: Disappearance of all target lesions) or a Partial Response (PR: at least a 30% decrease in the sum of diameters of target lesions) per Response Evaluation Criteria In Solid Tumours version 1.1 (RECIST 1.1). ORR will be assessed by blinded independent central review (BICR).

Up to approximately 3 years
Part 2: Duration of Response (DOR)
Aikaikkuna: Up to approximately 3 years

For participants who demonstrate a confirmed Complete Response (CR: disappearance of all target lesions) or Partial Response (PR: at least a 30% decrease in the sum of diameters of target lesions) per Response Evaluation Criteria In Solid Tumors Version 1.1 (RECIST 1.1), DOR is defined as the time from first documented evidence of CR or PR until progressive disease (PD) or death. Per RECIST 1.1, PD is defined as at least a 20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. The appearance of one or more new lesions is also considered PD. DOR as assessed by Blinded Independent Central Review (BICR) will be presented.

Up to approximately 3 years
Part 2: PFS - Cohort A-2 Arm 2 and Arm 3
Aikaikkuna: Up to approximately 3 years

PFS is defined as the time from randomization to the first documented progressive disease (PD) or death due to any cause, whichever occurs first as assessed by Response Criteria in Solid Tumors Version 1.1 (RECIST 1.1). PD is defined as ≥20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of ≥5 mm. The appearance of one or more new lesions is also considered PD. PFS as assessed by blinded independent central review (BICR) will be presented.

Up to approximately 3 years
Part 2: Overall Survival (OS)
Aikaikkuna: Up to approximately 5 years

OS is defined as the time from the first dose of study treatment to death due to any cause.

Up to approximately 5 years
Part 2: Number of Participants with One or More AEs
Aikaikkuna: Up to approximately 3 years

An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The number of participants who discontinue study intervention due to an AE will be reported.

Up to approximately 3 years
Part 2: Number of Participants who Discontinue Study Intervention Due to an AE
Aikaikkuna: Up to approximately 3 years

An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The number of participants who discontinue study intervention due to an AE will be reported.

Up to approximately 3 years

Yhteistyökumppanit ja tutkijat

Täältä löydät tähän tutkimukseen osallistuvat ihmiset ja organisaatiot.

Yhteistyökumppanit

Tutkijat

  • Opintojohtaja: Medical Director, Merck Sharp & Dohme LLC

Julkaisuja ja hyödyllisiä linkkejä

Tutkimusta koskevien tietojen syöttämisestä vastaava henkilö toimittaa nämä julkaisut vapaaehtoisesti. Nämä voivat koskea mitä tahansa tutkimukseen liittyvää.

Opintojen ennätyspäivät

Nämä päivämäärät seuraavat ClinicalTrials.gov-sivustolle lähetettyjen tutkimustietueiden ja yhteenvetojen edistymistä. National Library of Medicine (NLM) tarkistaa tutkimustiedot ja raportoidut tulokset varmistaakseen, että ne täyttävät tietyt laadunvalvontastandardit, ennen kuin ne julkaistaan ​​julkisella verkkosivustolla.

Opi tärkeimmät päivämäärät

Opiskelun aloitus (Todellinen)

Tiistai 15. huhtikuuta 2025

Ensisijainen valmistuminen (Arvioitu)

Tiistai 27. maaliskuuta 2029

Opintojen valmistuminen (Arvioitu)

Perjantai 7. helmikuuta 2031

Opintoihin ilmoittautumispäivät

Ensimmäinen lähetetty

Torstai 20. helmikuuta 2025

Ensimmäinen toimitettu, joka täytti QC-kriteerit

Torstai 20. helmikuuta 2025

Ensimmäinen Lähetetty (Todellinen)

Tiistai 25. helmikuuta 2025

Tutkimustietojen päivitykset

Viimeisin päivitys julkaistu (Todellinen)

Perjantai 13. marraskuuta 2026

Viimeisin lähetetty päivitys, joka täytti QC-kriteerit

Torstai 12. marraskuuta 2026

Viimeksi vahvistettu

Sunnuntai 1. marraskuuta 2026

Lisää tietoa

Tähän tutkimukseen liittyvät termit

Yksittäisten osallistujien tietojen suunnitelma (IPD)

Aiotko jakaa yksittäisten osallistujien tietoja (IPD)?

JOO

IPD-suunnitelman kuvaus

https://trialstransparency.msdclinicaltrials.com/pdf/ProcedureAccessClinicalTrialData.pdf

Lääke- ja laitetiedot, tutkimusasiakirjat

Tutkii yhdysvaltalaista FDA sääntelemää lääkevalmistetta

Joo

Tutkii yhdysvaltalaista FDA sääntelemää laitetuotetta

Ei

Nämä tiedot haettiin suoraan verkkosivustolta clinicaltrials.gov ilman muutoksia. Jos sinulla on pyyntöjä muuttaa, poistaa tai päivittää tutkimustietojasi, ota yhteyttä register@clinicaltrials.gov. Heti kun muutos on otettu käyttöön osoitteessa clinicaltrials.gov, se päivitetään automaattisesti myös verkkosivustollemme .

Tilaa